Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
CYTK filing reports an intended sale of 22,000 shares of Common Stock on 04/07/2026 following the exercise of stock options for cash. The filing lists brokerage placement with Morgan Stanley Smith Barney LLC and discloses prior sales by Fady Malik of 12,033 and 2,907 shares on 03/17/2026 and 03/09/2026, respectively, with disclosed gross proceeds.
Insider Robert Blum reported planned and recent disposals of Cytek Biosciences common stock via Form 144. The filing lists 45,000 Restricted Stock Units to be sold and shows two reported disposals in the past three months: 36,601 shares for $2,274,752.15 and 7,931 shares for $481,570.32. The cover lists an aggregate value of $2,965,950.00 and a figure of 123,162,807 shown alongside the 04/01/2026 date.
Cytokinetics Inc President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $66.63 per share. Following the sale, he directly holds 422,830 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTK filing notifies a proposed sale of 3,639 Restricted Stock Units dated 03/06/2026. The filing also lists multiple 10b5-1 dispositions by Andrew Callos between 01/02/2026 and 03/18/2026, including sales of 15,000 shares on 03/05/2026 and other dated transactions with reported proceeds.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 3,639 shares of Common Stock in an open-market transaction at $65.00 per share. The sale occurred on March 31, 2026. After this transaction, he continues to hold 66,004 shares of Cytokinetics Common Stock directly.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A for Cytokinetics Inc. The amendment states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Cytokinetics Common Stock, representing 0% of the class as shown in the filing dated 03/13/2026 with a signature on 03/26/2026. The filing explains certain subsidiaries and business divisions will report ownership separately in reliance on SEC Release No. 34-39538.
Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share. According to the footnote, this was a company-compelled sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting, rather than a discretionary sale. After the transaction, Lee directly holds 87,127 shares, indicating he retains a substantial equity position.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.
These sell‑to‑cover transactions were executed in two tranches and are tied to compensation, rather than discretionary trading. Following the sales, Callos directly holds 71,573 Cytokinetics shares, maintaining a substantial equity stake in the company.
CYTOKINETICS INC EVP of R&D Fady Malik reported tax-related stock sales. On the reported date, he sold a total of 12,033 shares of common stock in open-market transactions at $62.15 per share.
Footnotes state these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, indicating they were driven by taxes rather than discretionary selling. After the transactions, he continued to hold 153,902 shares directly.
Cytokinetics Inc. President & CEO Robert I. Blum reported an open-market sale of 36,601 shares of common stock at $62.15 per share. According to the footnotes, these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, rather than discretionary sales.
After these transactions, Blum holds 430,330 shares of common stock directly. In addition, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.